x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology On The Go

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology

science medicine

All Episodes

18:45

S1 Ep56: Oncology Peer Review On-The-Go: Current...

Oncology On The Go ·

2022/08/09

Juan Pablo Alderuccio, MD, assistant professor of medicine in the Division of Hematology, Department of Medicine at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine in Florida, spoke with CancerNetwork® about his review published in the journal ONCOLOGY® titled, Current Treatments in Marginal Zone Lymphoma. In the article, Alderuccio explored current approaches to the diagnosis and treatment of marginal zone lymphoma. He also touched on his strategies

en-us

14:02

S1 Ep55: Oncology Peer Review On-The-Go: The...

Oncology On The Go ·

2022/07/25

Kira MacDougall, MD, a first year fellow at the University of Oklahoma, and Muhammad Rafay Khan Niazi, MD, a third year resident of Internal Medicine at Staten Island University Hospital, spoke with CancerNetwork® about research published in the journal ONCOLOGY® titled, The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study. MacDougall and Niazi discuss the clinical utility of absolute lymphocyte

en-us

18:47

S1 Ep54: Oncology Peer Review On-The-Go: Focus of...

Oncology On The Go ·

2022/07/11

Kirk E. Cahill, MD, and Sonali M. Smith, MD, both of the Department of Medicine, Section of Hematology/Oncology at the University of Chicago Medicine Comprehensive Cancer Center in Chicago, Illinois, spoke about their manuscript titled, ‘Follicular Lymphoma: a Focus on Current and Emerging Therapies,’ that was recently published in the journal ONCOLOGY®. In the review, the authors explore current approaches to the diagnosis and treatment of follicular lymphoma, with a focus on emerging

en-us

44:23

S1 Ep57: Oncology Peer Review On-The-Go: Paolo...

Oncology On The Go ·

2022/06/30

In the inaugural Twitter Spaces edition of the Oncology Peer Review On-The-Go podcast hosted by CancerNetwork®, Paolo Tarantino, MD, a clinical research fellow at Dana-Farber Cancer Institute, and Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber as well as an associate professor of medicine at Harvard Medical School, reviewed presentations in breast cancer research from the 2022 American Society

en-us

13:19

S1 Ep52: Oncology Peer Review On-The-Go: Financial...

Oncology On The Go ·

2022/06/27

Suneel D. Kamath, MD, of the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, spoke with the editorial team of the journal ONCOLOGY® about his published manuscript titled, ‘Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and Oncology.’ Suneel and colleagues set out to determine how financial conflicts of interest could be used as a surrogate for the trajectory of early-career oncologists and junior faculty at academic

en-us

16:19

S1 Ep51: Oncology Peer Review On-The-Go: Academic...

Oncology On The Go ·

2022/06/20

Nora Janjan, MD, MPSA, MBA, who sits on the editorial advisory board for the journal ONCOLOGY®, spoke about her perspective titled, ‘Academic Promotion and Oncology Drug Development: Role, Responsibilities, and Integrity.’ In the article, Janjan explores the role conflicts of interests (COIs) play in research integrity and how individual investigators are upholding their end of the deal by practicing safe reporting of relationships with the industry. Her narrative complements a cross-sectional

en-us

21:08

S1 Ep25: Oncology Peer Review On-The-Go: Successful...

Oncology On The Go ·

2022/05/30

This week, CancerNetwork® spoke with Judd W. Moul, MD, editorial board member for the journal ONCOLOGY® and James H. Semans, MD, Distinguished Professor of Urologic Surgery at Duke University School of Medicine, leads a discussion with medical student Kostantinos E. Morris, from Duke University School of Medicine, on research recently published in the journal ONCOLOGY®titled, ‘Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative

en-us

22:24

S2 Ep25: Between the Lines™ Podcast: Updates in Use...

Oncology On The Go ·

2022/05/20

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma. As part of its Between the Lines™ video series, CancerNetwork® spoke with Paul G. Richardson, MD, clinical program leader and director of Clinical Research for the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts, and Christina Gasparetto, MD, professor of medicine at Duke University Medical School in

en-us

11:45

S1 Ep49: Tanios Bekaii-Saab, MD, and Colleagues...

Oncology On The Go ·

2022/05/16

This week, CancerNetwork turns to the second part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, continues the conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke

en-us

16:07

S1 Ep50: Tanios Bekaii-Saab, MD, and Experts Examine...

Oncology On The Go ·

2022/05/16

This week, CancerNetwork looks at the final part of its 3-part series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, concludes his conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke

en-us

16:46

S1 Ep48: Tanios Bekaii-Saab, MD, Talks COLOMATE...

Oncology On The Go ·

2022/05/09

This week, CancerNetwork kicks off the first of a 3-part podcast series focused on colorectal cancer. Tanios Bekaii-Saab, MD, a gastrointestinal cancers (GI) medical oncologist at the Mayo Clinic Cancer Center, leads a conversation with Kristen Ciombor, MD, MSCI, a GI medical oncologist and associate professor of medicine at Vanderbilt-Ingram Cancer Center, and John Strickler, MD, a GI medical oncologist, associate professor of medicine, and co-leader of the Molecular Tumor Board at Duke University

en-us

34:36

S2 Ep24: OncView™ Podcast: Advances in Systemic...

Oncology On The Go ·

2022/05/06

As part of its OncView™ program, CancerNetwork hosted a discussion Lori Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital in Boston, who shared her perspective on updates in the treatment of second-line radioiodine-refractory differentiated thyroid cancer, or DTC. In the video series, some of the content discussed included: · Presentation and Disease Course of Differentiated

en-us

30:07

S2 Ep23: OncView™ Podcast: Safety and Efficacy of...

Oncology On The Go ·

2022/04/29

As part of its OncView™ video series, CancerNetwork® spoke with David H. Aggen, MD, PhD, of the Memorial Sloan Kettering Cancer Center, Robert S. Alter, MD, of the John Theurer Cancer Center, Arnab Basu, MD, MPH, of the O’Neal Comprehensive Cancer Center, Mehmet Asim Bilen, MD, of Winship Cancer Institute, and Chung-Han Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, who shared their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and commented on

en-us

27:37

S2 Ep22: Between the Lines™ Podcast: Mobocertinib Use...

Oncology On The Go ·

2022/04/27

OncView™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC As part of its OncView™ video series, CancerNetwork® spoke with Gregory Riely, MD, PhD, vice chair of Clinical Research in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, and Tarek Mekhail, MD, a hematologic oncologist from Advent Health in Florida, about patients with EGFR exon 20 insertion-positive metastatic non–small cell lung cancer who recieved

en-us

8:28

S1 Ep47: Characterization of Blood-Based Molecular...

Oncology On The Go ·

2022/04/25

This week, CancerNetwork® spoke with Christine Chung, DO, of the Swedish Medical Center, Englewood, Colorado, about “Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma,” a retrospective review published in the journal ONCOLOGY. Chung detailed this research, which characterizes the mutational landscape of patients with metastatic pancreatic adenocarcinoma who received blood-based molecular profiling. A total of 77 consecutive patients were included in the

en-us

13:00

S1 Ep46: PARP Inhibitors as Maintenance Therapy for...

Oncology On The Go ·

2022/04/11

This week, CancerNetwork® spoke with Muhammad Niazi, MD, resident in internal medicine at Staten Island University Hospital, and Alexander Bershadskiy, MD, attending physician at Staten Island University Hospital, about a meta-analysis published in ONCOLOGY titled, “Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.” The final analysis evaluated 3 randomized clinical trials. A fixed model showed a

en-us

21:01

S2 Ep21: OncView™ Podcast: EGFR Exon 20 Insertion as...

Oncology On The Go ·

2022/04/08

As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions. In the video series, Piotrowska discussed the following: · Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions ·

en-us

25:24

S2 Ep20: Between the Lines™ Podcast: ctDNA as a...

Oncology On The Go ·

2022/04/05

As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer. In

en-us

43:51

S2 Ep19: OncView™ Podcast: Immunotherapy Response...

Oncology On The Go ·

2022/04/02

As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the melanoma center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to monitor responses in patients properly. In the video series, Kirkwood discussed the following: · Treatment Options for Melanoma · Considerations for Immunotherapy Use When Treating Melanoma · Monitoring Responses to Melanoma Therapy ·

en-us

18:12

S2 Ep18: OncView™ Podcast: Immunotherapy Response...

Oncology On The Go ·

2022/03/30

As part of its OncView™ video series, CancerNetwork® spoke with Roy Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, about currently available treatment options and strategies in immunotherapy for treating non–small cell lung cancer (NSCLC). In the video series, Herbst discussed the following: · Treatment Options in Non–Small Cell Lung Cancer · Monitoring Response to Therapy in NSCLC · Role of ctDNA in

en-us

222 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter